JodiLynLaytonMD

Oncology • New Orleans, LA

Physician

Join to view full profile

Dr. Layton is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Layton's full profile

Already have an account?

Office
150 S Liberty St
New Orleans, LA 70112
Phone+1 504-988-6300

Fax+1 504-988-6348

Education & Training

Brown UniversityFellowship, Hematology and Medical Oncology, 2009 - 2012
Tulane UniversityResidency, Internal Medicine, 2005 - 2008
The University of Texas Health Science Center at San AntonioClass of 2005

Certifications & Licensure

RI State Medical License 2009 - 2026
LA State Medical License 2007 - 2025
MA State Medical License 2011 - 2011
American Board of Internal Medicine Medical Oncology

Clinical Trials

Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin Start of enrollment: 2014 Jul 01
Terminated
Phase 2
Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis Start of enrollment: 2013 May 01
Unknown status
Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC Start of enrollment: 2019 Jan 25
Terminated
Phase 2

Publications & Presentations

PubMed

5 citations
Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients.
Rachel A. Sabol, Elisa Ledet, Ellen Jaeger, Whitley Hatton, Marcus Marie Moses
The Prostate. 2021-05-01
30 citations
Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.
Elisa Ledet, Earle F. Burgess, Alexandra O. Sokolova, Ellen Jaeger, Whitley Hatton
The Prostate. 2021-05-01
13 citations
Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort.
Pedro C. Barata, Whitley Hatton, Arpita Desai, Vadim S. Koshkin, Ellen Jaeger
Frontiers in Oncology. 2020-10-22